LoginRegister
    Biomarck Pharma starts phase 2 trial of BIO-11006 for Non-Small Cell Lung CancerBiomarck Pharma starts phase 2 trial of BIO-11006 for Non-Small Cell Lung Cancer
    Now criminal probe against JnJ for denying presence of carcinogens in Baby Powder: ReportNow criminal probe against JnJ for denying presence of carcinogens in Baby Powder: Report
    Biocon Chief Kiran Mazumdar Shaw, husband donate over Rs 51 crore to University of GlasgowBiocon Chief Kiran Mazumdar Shaw, husband donate over Rs 51 crore to University of Glasgow
    Dr Reddys gets 5 USFDA observations for Bollaram plantDr Reddys gets 5 USFDA observations for Bollaram plant
    Sandoz launches SYMJEPI Injection in US to help treat allergic reactionsSandoz launches SYMJEPI Injection in US to help treat allergic reactions
    Valeo Pharma launches Onstryv for treating Parkinsons disease in CanadaValeo Pharma launches Onstryv for treating Parkinsons disease in Canada
    Reckitt Benckiser pays USD 1.4 billion to settle opioid treatment spatReckitt Benckiser pays USD 1.4 billion to settle opioid treatment spat
    NPPA regulatory measures primarily triggered tough days for hospital sector, says IcraNPPA regulatory measures primarily triggered tough days for hospital sector, says Icra
    FIRST: Intas Pharma launches Romiplostim to treat chronic ITP in IndiaFIRST: Intas Pharma launches Romiplostim to treat chronic ITP in India
    Piramal cuts short-term borrowings, reduces dependence on CPs as NBFC crisis lingersPiramal cuts short-term borrowings, reduces dependence on CPs as NBFC crisis lingers
    Sterling Group: Government scraps Dahej port contract given to absconding Sandesara brothersSterling Group: Government scraps Dahej port contract given to absconding Sandesara brothers
    Gilead Sciences chooses Chengdu Hi-tech Zone for Western China Operation Center projectGilead Sciences chooses Chengdu Hi-tech Zone for Western China Operation Center project
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X